Galectin Therapeutics (GALT) Tops Q3 EPS by 5c

Galectin Therapeutics (NASDAQ: GALT) reported Q3 EPS of ($0.13), $0.05 better than the analyst estimate of ($0.18).

For earnings history and earnings-related data on Galectin Therapeutics (GALT) click here.

You May Also Be Interested In

• Gulfport Energy and Mobility Global to join S&P SmallCap 600
• Apogee Enterprises (APOG) Tops Q1 EPS by 16c, Beats on Revenue; Offers FY27 Guidance
• Uranium Royalty Corp. sets shareholder vote on $1.14B Sweetwater deal